Previous Close | 0.7300 |
Open | 0.7300 |
Bid | 0.0000 |
Ask | 1.1000 |
Strike | 43.00 |
Expire Date | 2024-05-31 |
Day's Range | 0.7300 - 0.7300 |
Contract Range | N/A |
Volume | |
Open Interest | 616 |
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
DEERFIELD, Ill., May 13, 2024--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insuffici
Baxter International Inc. ( NYSE:BAX ) will pay a dividend of $0.29 on the 1st of July. This means the annual payment...